Lower risk of severe checkpoint inhibitor toxicity in more advanced disease

Rik J. Verheijden, Anne M. May, Christian U. Blank, Astrid A. M. van der Veldt, Marye J. Boers-Sonderen, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Alfonsus J. M. van den Eertwegh, Jan Willem B. de Groot, Jacobus J. M. van der Hoeven, Geke A. P. Hospers, Djura Piersma, Rozemarijn S. van Rijn, Albert J. ten Tije, Gerard Vreugdenhil, Michiel C. T. van Zeijl, Michel W. J. M. Wouters, John B. A. G. Haanen, Ellen Kapiteijn, Karijn P. M. Suijkerbuijk*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Web of Science)
Original languageEnglish
Article number000945
Number of pages6
JournalESMO Open
Volume5
Issue number6
DOIs
Publication statusPublished - 2020

Keywords

  • checkpoint inhibition
  • immune-related adverse event (irAE)
  • anti-PD1
  • melanoma
  • DMTR
  • IMMUNE CHECKPOINTS
  • ADVERSE EVENTS
  • CANCER
  • MELANOMA
  • IPILIMUMAB
  • IMMUNOTHERAPY
  • ASSOCIATION
  • MONOTHERAPY
  • NIVOLUMAB
  • SURVIVAL

Cite this